Setback for Lilly, gain for Plavix?

When FDA delayed its decision on Eli Lilly's clot-buster prasugrel, a.k.a. Effient, it sliced at least three months off the time Lilly might have to win market share from the commonly used blood thinner Plavix. Doing so quickly is crucial, because Bristol-Myers Squibb and Sanofi-Aventis' Plavix goes off patent by 2011--and cheap generic versions are likely to drain away even more of the market. Report

Suggested Articles

It’s final: England won’t be covering AZ’s quick-selling Tagrisso in previously untreated non-small cell lung cancer patients with EGFR mutatations.

Top J&J meds have managed to hang onto market share in the face of new generics and biosims, but the drugmaker expects the pain to continue in 2020.

Lonza’s search for a new CEO is expected to be wrapped up this year as the CDMO homes in on a list of veterans from outside the company.